Good, bad & uncertainty of new patent guidelines
This article was originally published in Scrip
Executive Summary
Ever since the US Patent & Trademark Office (US PTO) issued guidance this past March aimed at addressing two Supreme Court rulings that rocked the life sciences sectors – Association for Molecular Pathology v Myriad Genetics and Mayo Collaborative Services v Prometheus Laboratories – unsatisfied patent lawyers and biopharmaceutical firms have eagerly awaited revisions to the agency's document.